Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | Vorinostat | HDAC | Misc | 2.217 | -0.1134 | 0.1610 | 0.0705 | 1.6271 | 2.8626 | 0.99345 |
| BT-20 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 1.0152 | -0.0415 | -0.0034 | 0.0000 | Inf | -7.4504 |
| BT-20 | Doxorubicin | Chemo | Chemotherapy | 0.0087386 | -0.4813 | 0.8279 | 0.3024 | 1.4443 | 0.013048 | 0.9861 |
| BT-20 | ABT-737 | Bcl2/XL | Misc | 12.6171 | 0.5926 | 0.0250 | 0.0397 | 1.1740 | 32.0424 | 0.93473 |
| BT-20 | Bleomycin | Radiation | Misc | 0.4878 | -0.1286 | 0.3764 | 0.0970 | 0.9564 | 0.75174 | 0.99474 |
| BT-20 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.018077 | -0.3749 | 0.7363 | 0.2005 | 0.7541 | 0.028401 | 0.95352 |
| BT-20 | AZD7762 | CHK1/2 | Cell cycle | 1.081 | -0.5785 | 0.2831 | 0.1722 | 1.5948 | 1.8464 | 0.99406 |
| BT-20 | Cisplatin | Chemo | Chemotherapy | 0.79098 | -0.3367 | 0.3338 | 0.0794 | 0.9579 | 1.7289 | 0.98666 |
| BT-20 | Etoposide | Topo II | Chemotherapy | 0.30148 | -0.3834 | 0.4591 | 0.1362 | 1.2176 | 0.48057 | 0.99643 |
| BT-20 | Saracatinib | SRC | MAPK/nRTK | 4.8514 | 0.3103 | 0.1591 | 0.0406 | 0.5845 | 31.7814 | 0.9851 |
| BT-20 | A-1210477 | Mcl-1 | Misc | 14.9935 | 0.8209 | -0.0262 | 0.0007 | 4.9994 | 12.3309 | 0.67398 |
| BT-20 | Olaparib | PARP | Misc | 15.2735 | 0.6064 | 0.0657 | 0.0087 | 0.8235 | 57.982 | 0.94742 |
| BT-20 | Ipatasertib | AKT | PI3K/mTOR | 0.64483 | 0.1015 | 0.3111 | 0.0476 | 0.7459 | 0.59909 | 0.98219 |
| BT-20 | Alpelisib | PI3Ka | PI3K/mTOR | 2.0326 | -0.1181 | 0.2014 | 0.0639 | 0.8192 | 7.7705 | 0.99071 |
| BT-20 | Abemaciclib | CDK4/6 | Cell cycle | 0.061268 | -0.2160 | 0.5694 | 0.0435 | 0.4177 | 0.17789 | 0.93347 |
| BT-20 | Palbociclib | CDK4/6 | Cell cycle | 0.043794 | 0.1624 | 0.3972 | 0.0216 | 1.2275 | 0.030066 | 0.99055 |
| BT-20 | Volasertib | PLK | Cell cycle | 0.0056337 | -0.5339 | 0.7904 | 0.3461 | 2.3226 | 0.0076094 | 0.99851 |
| BT-20 | Dinaciclib | pan CDK | Cell cycle | 0.018482 | -0.6979 | 0.6791 | 0.3193 | 3.4864 | 0.02362 | 0.99822 |
| BT-20 | Taxol | Chemo | Chemotherapy | 0.0020158 | -0.5760 | 0.9854 | 0.4456 | 2.0677 | 0.0028795 | 0.99355 |
| BT-20 | Topotecan | Topo I | Chemotherapy | 0.012333 | -0.6410 | 1.0284 | 0.3794 | 0.9448 | 0.029071 | 0.99592 |
| BT-20 | Dasatinib | BCR/ABL | MAPK/nRTK | 0.67985 | 0.2835 | 0.3289 | 0.0839 | 0.5423 | 0.27245 | 0.98321 |
| BT-20 | Trametinib | MEK | MAPK/nRTK | 2.3446 | 0.5034 | 0.1768 | 0.0535 | 0.6346 | 0.053945 | 0.96232 |
| BT-20 | Luminespib | HSP90 | Misc | 0.005967 | -0.0490 | 0.5621 | 0.1453 | 4.4759 | 0.0060667 | 0.99656 |
| BT-20 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.3900 | 0.5932 | 0.0889 | 0.0000 | Inf | 0.031152 |
| BT-20 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.008897 | -0.2891 | 0.5365 | 0.1367 | 0.8675 | 0.012533 | 0.97198 |